
Samsung is looking into more AI devices - potentially including earrings and necklaces
AI could enable a new wave of devices that allow users to communicate and get things done more quickly without having to take out a phone, Won-joon Choi, chief operating officer for Samsung's mobile experience division, told CNN this week.
For Samsung, these types of new devices could be something you wear around your neck, dangle from your ears or slip on your finger.
'We believe it should be wearable, something that you shouldn't carry, (that) you don't need to carry,' he said. 'So it could be something that you wear, glasses, earrings, watches, rings and sometimes (a) necklace.'
Choi's comments underscore the opportunity tech giants see to develop new hardware products around AI, a technology that some say is expected to be as impactful as the internet itself.
AI services like OpenAI's ChatGPT and Google's Gemini have moved beyond basic text prompts and are getting better at handling complex tasks. That's led tech giants to look into devices that require less manual input than smartphones, which largely require typing and swiping on screens.
That search is already in full swing, starting with smart glasses. Meta has touted its AI-powered Ray-Ban smart glasses, of which 2 million have been sold since 2023, as a success. The Facebook parent also recently acquired a minority stake in Ray-Ban parent company EssilorLuxottica, according to Bloomberg, further indicating the company's interest in AI-powered wearable gadgets.
Samsung, Google and Snap are also developing smart glasses, while OpenAI and ex-Apple designer Jony Ive are collaborating on a mysterious new AI device for next year.
When CNN asked Choi whether Samsung is actively looking into developing earrings or other smart jewelry, like a pendant or bracelet, Choi said the company is 'looking at all kinds of possibilities.'
'What do you wear? Glasses, earrings… necklaces, watches and rings, something like those,' he said.
However, that doesn't mean those possibilities will become products. Samsung and other tech companies routinely develop prototypes and evaluate new technologies internally without bringing them to market.
Some tech startups have already unsuccessfully tried to develop new AI gadgets to replace smartphones at certain tasks.
The Humane AI Pin, created by a pair of Apple veterans, flopped because of its high price and buggy performance. The company shut down the product and sold parts of itself to computing giant HP in February. Another device called the Rabbit R1 also launched to a lackluster reception last year, although it's undergone significant updates since then. And a startup called Friend created an AI necklace that's meant to be a digital companion, although its launch has been delayed until the third quarter of this year.
Samsung's approach, unlike some of these options, will involve a device that's a companion to your phone rather than a standalone product, similar to the company's smartwatches, according to Choi.
And the company's upcoming smart glasses, which it hasn't revealed many details about yet, could be just the start.
'We are actively working on glasses, but some people do not want to wear glasses because they change their look,' he said. 'So we are also exploring other types of devices.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Infosys Collaborates with AGCO to Deliver IT and HR Operations Transformation
Building on a longstanding relationship to enhance AGCO's operational framework for growth by leveraging Infosys Cobalt and Infosys Topaz BENGALURU, India, July 22, 2025 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced the extension of its strategic collaboration with AGCO Corporation (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision agriculture technology. This new engagement spans IT infrastructure and HR operations, empowering AGCO with an efficient and future-ready operational framework. The transformation aims to enhance user experience through responsive IT solutions, simplicity, consistency and cost reductions via standardized processes as well as accelerated efficiency with scalable tools and automation technologies. Building on the trust fostered through a strategic digital transformation collaboration, the two companies are working together on the following critical areas: HR operations aimed at elevating employee experience, streamlining processes and driving efficiency within AGCO's human resource functions, in collaboration with the Infosys BPM practice. IT infrastructure operations leveraging best-in-class offerings like Infosys Polycloud, a part of Infosys Cobalt, along with automation technologies aimed at simplifying, standardizing, and optimizing AGCO's IT ecosystem. In an effort to simplify AGCO's operations and realize cost efficiencies, Infosys is using generative AI for knowledge management, problem analysis, categorization and incident resolution. Powered by Infosys Topaz, an AI-first set of services, solutions and platforms using generative AI technologies, Infosys will work towards ensuring access to next-gen tools and technology vital for AGCO's growth trajectory. "At AGCO, we're committed to delivering excellence in everything we do, always putting Farmers First. Collaborating with Infosys is intended to enable us to create a responsive, streamlined and innovative operational ecosystem within IT and other functions that allows our teams to focus on critical and strategic initiatives that center on the farmer," said Viren Shah, Chief Digital & Information Officer, AGCO Corporation. "By leveraging our strengths in AI, automation and digital expertise, our collaboration with AGCO reflects Infosys' commitment to delivering tangible outcomes that drive enhanced user experience, efficiencies and lower operational costs," said Jasmeet Singh, Executive Vice President and Global Head of Manufacturing, Infosys. "This collaboration underscores the power of innovation and trust that has been the hallmark of our relationship with AGCO over the years." About Infosys Ltd. Infosys is a global leader in next-generation digital services and consulting. Over 320,000 of our people work to amplify human potential and create the next opportunity for people, businesses, and communities. We enable clients in more than 59 countries to navigate their digital transformation. With over four decades of experience in managing the systems and workings of global enterprises, we expertly steer clients, as they navigate their digital transformation powered by cloud and AI. We enable them with an AI-first core, empower the business with agile digital at scale and drive continuous improvement with always-on learning through the transfer of digital skills, expertise, and ideas from our innovation ecosystem. We are deeply committed to being a well-governed, environmentally sustainable organization where diverse talent thrives in an inclusive workplace. Visit to see how Infosys (NSE, BSE, NYSE: INFY) can help your enterprise navigate your next. About AGCO AGCO (NYSE: AGCO) is a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology. AGCO delivers value to farmers and OEM customers through its differentiated brand portfolio including leading brands Fendt®, Massey Ferguson®, PTx and Valtra®. AGCO's full line of equipment, smart farming solutions and services helps farmers sustainably feed our world. Founded in 1990 and headquartered in Duluth, Georgia, USA, AGCO had net sales of approximately $11.7 billion in 2024. For more information, visit Safe Harbor Certain statements in this release concerning our future growth prospects, or our future financial or operating performance, are forward-looking statements intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results or outcomes to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, increased competition for talent, our ability to attract and retain personnel, increase in wages, investments to reskill our employees, our ability to effectively implement a hybrid work model, economic uncertainties and geo-political situations, technological disruptions and innovations such as artificial intelligence ("AI"), generative AI, the complex and evolving regulatory landscape including immigration regulation changes, our ESG vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity, capital resources, our corporate actions including acquisitions, and cybersecurity matters. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2025. These filings are available at Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law. SOURCE Infosys Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth. The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma, is a significant factor driving the adoption of AI in ophthalmology. As the population ages, the incidence of these diseases increases, creating a need for efficient and accurate diagnostic tools. For instance, according to the CDC, the estimated number of Americans living with glaucoma in 2022 was 4.22 million. AI algorithms can rapidly analyze complex retinal images, facilitating early detection and treatment. For instance, AI systems have shown high sensitivity and specificity in identifying diabetic retinopathy, which allows for timely interventions and reduces the risk of vision loss. Moreover, integrating advanced imaging techniques such as Optical Coherence Tomography (OCT) with AI has revolutionized ophthalmic diagnostics. High-resolution imaging provides detailed views of ocular structures, which enhances diagnostic precision when analyzed by artificial intelligence (AI). The availability of large datasets from these imaging technologies allows for the training of robust AI models, improving their accuracy and reliability in clinical settings." Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB: AVAI), Alcon Inc. (NYSE: ALC), Bausch + Lomb Corporation (NYSE: BLCO), Johnson & Johnson (NYSE: JNJ), Tempus AI, Inc. (NASDAQ: TEM). Research And Markets continued: "Furthermore, teleophthalmology, the remote delivery of eye care services, has gained traction, especially in underserved regions. AI is crucial in this expansion by enabling automated analysis of retinal images, facilitating remote diagnosis, and reducing the need for in-person consultations. This approach increases access to eye care and optimizes resource utilization in healthcare systems. For instance, in June 2024, C3 Med-Tech, an ophthalmic health tech startup, raised USD 0.23 million to launch AI-enabled, portable eye screening devices. The funding is expected to support telemedicine integration, real-time disease detection, and expansion across India, aiming to reduce avoidable blindness, especially in underserved communities facing a shortage of ophthalmologists. Moreover, AI's ability to analyze and interpret data from Electronic Health Records (EHRs) facilitates personalized treatment plans in ophthalmology. AI predicts disease progression by assessing patient history, genetic information, and imaging data and recommends tailored interventions, further contributing to market growth." Avant Technologies, Inc. (OTCQB: AVAI) Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference - Avant Technologies, Inc. ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Cartagena, Colombia. The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in Latin America. Ainnova's CEO, Vinicio Vargas, who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego, Hugo Ocampo, and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems. In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova's AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy. If the program is successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through AAC. AAC has the worldwide licensing rights for Ainnova's technology portfolio, which includes Ainnova's Vision AI platform. CONTINUED… Read this and more news for Avant Technologies at: In other diabetes developments and happenings in the biotech market include: Alcon Inc. (NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, recently announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. "Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone," said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. "We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients." Bausch + Lomb Corporation (NYSE: BLCO), a leading global eye health company dedicated to helping people see better to live better, recently launched "Eyes Tell the Story: The Impact of Dry Eye." The campaign aims to educate about dry eye through personal stories, compelling imagery and new survey data, and encourages people with symptoms to speak with their eye doctor to find relief. Eyes Tell the Story builds upon Know Your Dry Eye, an educational campaign launched in 2024 that featured data and insights from the company's first State of Dry Eye survey, which showed the majority of Americans may not know that their eye symptoms are associated with eye dryness, despite the growing prevalence of dry eye. This year's survey, conducted among dry eye sufferers who are using either a prescription treatment or over-the-counter (OTC) product, further supports the need for more patient education and to dispel ongoing misconceptions surrounding dry eye. Johnson & Johnson (NYSE: JNJ) recently launched TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The TECNIS Odyssey IOL was first launched in the US in October 2024. The TECNIS Odyssey IOL is a full vision range intraocular lens (IOL), built on the TECNIS platform from Johnson & Johnson, which, according to the company, provides 2 times better contrast in low lighting than PanOptix. The TECNIS Odyssey combines advanced optics and proprietary materials, offering consistently clear, high-contrast vision, according to the company. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared ECG-AI device in Tempus' growing suite of next generation devices designed to identify patients at risk for a variety of cardiovascular conditions. "With Tempus ECG-Low EF, we're adding another powerful tool to the hands of clinicians to help them identify patients at risk for serious cardiovascular conditions much earlier in their care journey," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. "Detection of LVEF is essential for undiagnosed patients, and this technology enables us to deliver that capability at scale to transform patient care. The addition of a second FDA-cleared Tempus ECG-AI solution reflects our continued commitment to advancing AI-driven cardiology." DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements. Contact Information: Media Contact email: editor@ - +1(561)325-8757 View original content: SOURCE MarketNewsUpdates View original content: Sign in to access your portfolio
Yahoo
14 minutes ago
- Yahoo
China's market regulator suspends antitrust investigation into DuPont China
BEIJING (Reuters) -China's market regulator said in a statement on Tuesday that it had suspended the antitrust investigation into DuPont China Group, a subsidiary of the U.S. firm DuPont. The regulator launched an investigation into DuPont China in April for its alleged violation of the country's anti-monopoly law, amid a heated trade war between China and the Unites States. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data